NCT06267170尚未招募不适用
A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 288
- 主要终点
- Safety (Occurrence of ≥ Grade 3 AE)
研究概览
简要总结
This study collected data on patients with extensive stage small cell lung cancer treated with Adebrelimab to investigate its safety and efficacy
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sign informed consent and join the study voluntarily;
- •Patients diagnosed with extensive small cell lung cancer;
- •Age ≥18 years old;
- •Have at least one measurable lesion (according to RECIST 1.1);
- •The investigators judged that adebrelimab treatment was acceptable;
- •Contraception: Patients should agree that it must be used during the study period and within 6 months after the study ends Effective contraception;
排除标准
- •Allergic to adebrelimab and its excipients;
- •Patients who have also received other immune drugs or therapies;
- •Patients who are participating in other interventional studies;
- •patients with other malignant tumors;
- •Pregnant or lactating women;
- •The investigator considers that the patient is not suitable to participate in any other conditions of the study.
结局指标
主要结局
Safety (Occurrence of ≥ Grade 3 AE)
时间窗: End of each cycle (each cycle is 28 days)
The incidence of grade 3 or higher adverse events
次要结局
- PFS(End of every two cycles (each cycle is 28 days))
- ORR(End of every two cycles (each cycle is 28 days))
- OS(End of every two cycles (each cycle is 28 days))
- DCR(End of every two cycles (each cycle is 28 days))
研究者
Qiming Wang
Chief physician
Henan Cancer Hospital
相似试验
尚未招募
不适用
A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung CancerExtensive-stage Small Cell Lung Cancer (ES-SCLC)NCT06530797Shanghai Pulmonary Hospital, Shanghai, China2,000
尚未招募
2 期
Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene MutationsNon Small Cell Lung CancerNCT06299371Liaoning Tumor Hospital & Institute36
招募中
不适用
A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung CancerExtensive Stage Small Cell Lung CancerNCT06323265Hebei Medical University Fourth Hospital50
尚未招募
2 期
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung CancerSmall Cell Lung CarcinomaNCT06236997Henan Cancer Hospital48
招募中
2 期
Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles StudyEsophageal CancerNCT06663059Tang-Du Hospital80